BIIB34:BVMF
Biogen Inc BDR
R$230,10
0,00%
(0,00) 1D
4 Nov., 15:38:07 GMT-3 · BRL
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BIIB34...
Mkt. cap
37,46Â mjd
Avg. vol.
9,00
Volume
0,00
52-wk high
R$230,10
52-wk low
R$145,65
Shares outstanding
147,82Â m
No. of employees
8Â k
Mkt. cap
37,46Â mjd
Avg. vol.
9,00
Volume
0,00
52-wk high
R$230,10
52-wk low
R$145,65
Shares outstanding
147,82Â m
No. of employees
8Â k
News stories
From web sources and news partners
BigGo Finance
·
5 uur gelede
Goldman Sachs Sets 8,700 S&P 500 Target for 2027, Sees 14% Upside as AI Capex Peaks
The Motley Fool
·
4 uur gelede
Tesla Is Down 13% in 2026 While the S&P 500 Is Up. Here’s the 1 Catalyst Left This Year That Could Flip That.
24/7 Wall St.
·
3 uur gelede
Gilead Beat the S&P 500 by More Than 25 Points in the Past Year, but $1,000 From a Decade Ago Is Still Worth Less Than $3,500
Traders Union
·
2 uur gelede
Chris Ciovacco: Semiconductors SMH and S&P 500 SPY show several possible support areas
Profile
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate, diroximel fumarate, interferon beta-1a, peginterferon beta-1a, and natalizumab, all for the treatment of multiple sclerosis; nusinersen for the treatment of spinal muscular atrophy; omaveloxolone for the treatment of Friedreich's ataxia; tofersen for the treatment of ALS; and dimethyl fumarate for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars and has collaborations with Genentech for several drugs.
The company is ranked 424th on the Fortune 500 and 845th on the Forbes Global 2000. Wikipedia
About Biogen Inc BDR
CEOChris Viehbacher
Employees7,5Â k
Founded1978
HeadquartersCambridge, Massachusetts, Verenigde State van Amerika
SectorHealth Care
Industry-
Websitebiogen.com